Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 6/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CFD | P00746 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20488746 | 0.88 | ACHE (0.35) | BRD4ACHE | |
| SCHEMBL23613363 | 0.87 | BRD4 (0.36) | BRD4ACHE | |
| SCHEMBL20488757 | 0.84 | QPCT (0.39) | BRD4CFD | |
| SCHEMBL20488336 | 0.84 | DGAT2 (0.41) | BRD4CFD | |
| SCHEMBL29854911 | 0.84 | DGAT2 (0.41) | BRD4CFD | |
| SCHEMBL20487891 | 0.79 | HPGD (0.35) | BRD4ACHECFD | |
| SCHEMBL29854881 | 0.79 | HPGD (0.34) | BRD4CFD | |
| SCHEMBL23613367 | 0.77 | MGLL (0.44) | — | |
| SCHEMBL30525706 | 0.77 | ABCG2 (0.37) | CFD | |
| SCHEMBL29854934 | 0.74 | ESR1 (0.37) | CFD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3589287-B1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718626-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | DYRK1A 4695/4885BRD4 4560/4885ACHE 3052/4885 |
| US-12297205-B2 | Macrocyclic compounds for treatment of medical disorders | CFD, TFPI, CFH | DYRK1A 4695/4885BRD4 4560/4885ACHE 3052/4885 |
| US-20240059702-A1 | MACROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | DYRK1A 4695/4885BRD4 4560/4885ACHE 3052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.